Results 1 to 10 of about 2,446,428 (296)

Extraskeletal Ewing’s sarcoma of the mediastinum: Case report

open access: yesFrontiers in Oncology, 2023
BackgroundEwing sarcoma (ES) represents the second most common malignant bone tumor in children and young adults. ES is not a frequent finding in sites different from the skeletal.
Aldo Caltavituro   +15 more
doaj   +1 more source

Left Atrial Myxoma Presenting As a Stroke – An Unusual Case Scenario [PDF]

open access: yesPerspectives In Medical Research, 2021
The most common benign cardiac tumor is cardiac myxoma,accounting for around 50% of all primary cardiac tumors. Cardiac myxoma is an uncommon cause ofcardioembolic stroke.Overall,cardioembolic stroke accounts for approximately 30% of all ischemic ...
Mounika Pinninti1 , B.Syandhika1 ,Kasturi Ravinder Reddy2 ,Nikhil Mudgalkar3 ,Ashish Baviskar4
doaj   +1 more source

Case report: Using DNA short tandem repeats to confirm nongestational origin of pulmonary choriocarcinoma

open access: yesFrontiers in Oncology, 2022
Gestational trophoblastic neoplasias (GTN) are malignant neoplasms that occur in pregnant or recently pregnant women. Choriocarcinoma (CCA) is a highly aggressive and rare GTN, and cases outside the female genital tract are commonly seen as secondary ...
Filipa Ferreira da Silva   +5 more
doaj   +1 more source

Epstein-Barr virus infectious particles initiate B cell transformation and modulate cytokine response

open access: yesmBio, 2023
The Epstein-Barr virus (EBV) efficiently transforms primary B cells. Here, we show that this process starts immediately after cellular exposure to infectious viral particles.
Francesco Baccianti   +5 more
doaj   +1 more source

Does epidural analgesia modify the risk of complications after gastrectomy?

open access: yesNowotwory, 2021
INTRODUCTION: The surgical treatment of Gastric Cancer is associated with overall complication rates as high as 50%. The intent of this study was to assess the impact of epidural analgesia (EA) on postoperative complication rates among patients ...
Tomasz Olesiński   +6 more
doaj   +1 more source

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

open access: yesDisease Models & Mechanisms, 2022
There is a paucity of adequate mouse models and cell lines available to study lung squamous cell carcinoma (LUSC). We have generated and characterized two models of phenotypically different transplantable LUSC cell lines, i.e.
Karmele Valencia   +19 more
doaj   +1 more source

The roles of extracellular vesicles in the development, microenvironment, anticancer drug resistance, and therapy of head and neck squamous cell carcinoma

open access: yesJournal of Experimental & Clinical Cancer Research, 2021
Head and neck squamous cell carcinoma (HNSCC) is one of the main malignant tumours affecting human health, mainly due to delayed diagnosis and high invasiveness.
Xueying Wang   +7 more
doaj   +1 more source

Evaluation of the incidence of splenic hilar lymph node metastasis in patients operated on for esophagogastric junction cancer

open access: yesNowotwory, 2023
INTRODUCTION: The purpose of this study is to evaluate the effect of esophagogastric junction cancer (EGJC) staging on the risk of splenic hilar lymph node involvement. MATERIAL AND METHODS: 312 patients with EGJC after R0 surgery were analyzed; 118 (38%)
Tomasz Olesiński   +4 more
doaj   +1 more source

Episcleral brachytherapy as an effective alternative in vasoproliferative tumors [PDF]

open access: yesInternational Journal of Ophthalmology, 2018
The aim of this study is to assess the results of episcleral brachytherapy as treatment of retinal vasoproliferative tumors (RVTs) in a referral Intraocular Tumors Unit (ITU). A retrospective review of all patients diagnosed with vasoproliferative tumors
Marta Para Prieto   +5 more
doaj   +1 more source

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

open access: yesNature Communications, 2020
Immune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor ...
Daniel Baumann   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy